Search

Your search keyword '"Luis M. Ruilope"' showing total 1,009 results

Search Constraints

Start Over You searched for: Author "Luis M. Ruilope" Remove constraint Author: "Luis M. Ruilope"
1,009 results on '"Luis M. Ruilope"'

Search Results

1. Urinary extracellular vesicles as a monitoring tool for renal damage in patients not meeting criteria for chronic kidney disease

2. Glucose-Lowering Drugs and Primary Prevention of Chronic Kidney Disease in Type 2 Diabetes Patients: A Real-World Primary Care Study

3. Finerenone in Black Patients With Type 2 Diabetes and CKD: A Post hoc Analysis of the Pooled FIDELIO-DKD and FIGARO-DKD Trials

4. Finerenone in Hispanic Patients With CKD and Type 2 Diabetes: A Post Hoc FIDELITY Analysis

5. FINERENONE IN CHRONIC KIDNEY DISEASE AND TYPE 2 DIABETES: A FIDELITY ANALYSIS OF LEFT VENTRICULAR HYPERTROPHY

6. Physical Exercise in Resistant Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

8. Perfil metabolómico diferenciador asociado a la condición de normoalbuminuria en la población hipertensa

9. Fibroblast Growth Factor-23-Klotho Axis in Cardiorenal Syndrome: Mediators and Potential Therapeutic Targets

10. Systemic Inflammation Precedes Microalbuminuria in Diabetes

11. An Overview of FGF-23 as a Novel Candidate Biomarker of Cardiovascular Risk

15. Exercise Reduces Ambulatory Blood Pressure in Patients With Hypertension: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

16. Prevalencia de enfermedad renal crónica en España: impacto de la acumulación de factores de riesgo cardiovascular

17. Chronic kidney disease in Spain: Prevalence and impact of accumulation of cardiovascular risk factors

18. Immune system deregulation in hypertensive patients chronically RAS suppressed developing albuminuria

19. 2016 ESC GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF ACUTE AND CHRONIC HEART FAILURE

20. Oxidized Low-Density Lipoprotein Associates with Ventricular Stress in Young Adults and Triggers Intracellular Ca2+ Alterations in Adult Ventricular Cardiomyocytes

21. Prevalence and Clinical Characteristics of Refractory Hypertension

22. Rapid, Automated, and Specific Immunoassay to Directly Measure Matrix Metalloproteinase-9–Tissue Inhibitor of Metalloproteinase-1 Interactions in Human Plasma Using AlphaLISA Technology: A New Alternative to Classical ELISA

23. ANTIHYPERTENSIVE EFFICACY AND TOLERABILITY OFLERCANIDIPINE IN DAILY CLINICAL PRACTICE. THE ELYPSE STUDY

24. Progression of Renal Insufficiency in Patients with Essential Hypertension Treated with Renin Angiotensin Aldosterone System Blockers: An Electrocardiographic Correlation

25. Efficacy of Single-Pill Combination of Telmisartan 80 mg and Hydrochlorothiazide 25 mg in Patients with Cardiovascular Disease Risk Factors: A Prospective Subgroup Analysis of a Randomized, Double-Blind, and Controlled Trial

26. Cardiovascular and Renal Links along the Cardiorenal Continuum

27. Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis

28. Prevention of cardiorenal damage: importance of albuminuria

29. A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease

30. Renal denervation in the antihypertensive arsenal – knowns and known unknowns

31. Association of clinic and ambulatory heart rate parameters with mortality in hypertension

33. Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial

34. Author response for 'Effects of finerenone in persons with <scp>CKD</scp> and <scp>T2D</scp> are independent of <scp>HbA1c</scp> at baseline, <scp>HbA1c</scp> variability, diabetes duration and insulin use at baseline'

35. A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes

36. Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease

37. Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist use

38. 2021 Spanish Society of Hypertension position statement about telemedicine

39. Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes

40. Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes

41. Editorial commentary: Adequate blood pressure control unattainable without adequate recognition and treatment of primary aldosteronism

42. Use of chronic kidney disease blind spot to prevent cardiorenal outcomes

43. Author response for 'Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by GLP‐1RA use'

44. Abstract P351: Prognosis Of Different Forms Of Resistant Hypertension

45. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis

48. 826-P: Effect of Finerenone on Occurrence of Vision-Threatening Events in Patients with DR

49. 16-LB: Effects of Finerenone in Patients with CKD and T2D Are Independent of HbA1c at Baseline, HbA1c Variability, and Duration of Diabetes

50. 22-OR: Finerenone in Patients across the Spectrum of CKD and T2D by GLP-1RA Use

Catalog

Books, media, physical & digital resources